Quantro: Seed capital by Evotec and Boehringer

Quantro will combine and exploit innovative functional-genetic and transcriptomic technologies to generate a drug discovery pipeline that will transform the precision and scope of cell-based compound screens. By introducing “Transcriptional Fingerprinting” to drug discovery, the young company intends to revamp the scope of pharmacologic interventions in a variety of cellular, target and disease contexts. A prime focus will be the discovery and development of drug candidates blocking the activity of oncogenic transcription factors, a class of particularly promising therapeutic targets that has so far been deemed “undruggable”.

Founded by Dr Stefan Ameres and Dr Johannes Zuber as a spin-off from the Institute of Molecular Biotechnology and the Research Institute of Molecular Pathology, Quantro is headed by Chief Executive Officer Dr Dieter Nachtigall. The company is located in the Vienna Biocenter.

©european-biotechnology.com/am